Esme Kamphuis
Overview
Explore the profile of Esme Kamphuis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kamphuis E, Loman L, de Bruin-Weller M, Schuttelaar M
Acta Derm Venereol
. 2025 Jan;
105():adv41129.
PMID: 39780414
No abstract available.
2.
van der Rijst L, Kamphuis E, Schuttelaar M, Hurmuz R, Seyger M, Caron A, et al.
JAMA Dermatol
. 2024 Oct;
161(1):12-21.
PMID: 39412782
Importance: Dupilumab, methotrexate (MTX), and cyclosporine A (CsA) are valuable treatment options for pediatric patients with refractory moderate to severe atopic dermatitis (AD). Yet, comparative data on these treatments in...
3.
Boesjes C, Kamphuis E, de Graaf M, Spekhorst L, Haeck I, van der Gang L, et al.
JAMA Dermatol
. 2024 Aug;
160(10):1044-1055.
PMID: 39110432
Importance: Limited data are available on the long-term effectiveness and safety of dupilumab for atopic dermatitis (AD) in daily practice. Objective: To evaluate clinical effectiveness and reasons for discontinuation of...
4.
Zhang J, Boesjes C, Loman L, Kamphuis E, Romeijn M, Spekhorst L, et al.
J Am Acad Dermatol
. 2024 Apr;
91(2):300-311.
PMID: 38653344
Background: Long-term daily practice data on patient-reported benefits of dupilumab for atopic dermatitis (AD) remains limited. Objective: To evaluate patient-reported outcome measures (PROMs) and the safety of dupilumab in patients...
5.
Kamphuis E, Boesjes C, Loman L, Kamsteeg M, Haeck I, van Lynden-van Nes A, et al.
Acta Derm Venereol
. 2024 Feb;
104:adv19454.
PMID: 38323500
Limited daily practice data on the effect of abrocitinib in patients with atopic dermatitis are available. The aim of this multicentre prospective study is to evaluate the effectiveness and safety...
6.
Spekhorst L, Boesjes C, Loman L, Zuithoff N, Bakker D, Kamphuis E, et al.
Br J Dermatol
. 2023 May;
189(3):327-335.
PMID: 37177895
Background: Limited data are available regarding patient-centred dosing of dupilumab for atopic dermatitis (AD) in daily practice. Objectives: To evaluate our patient-centred dupilumab dosing regimen in daily practice, to assess...
7.
Voorberg A, Kamphuis E, Christoffers W, Schuttelaar M
Br J Dermatol
. 2023 May;
189(4):400-409.
PMID: 37170922
Background: Effective treatment options for patients with chronic hand eczema (CHE) are scarce. Dupilumab is licensed for the treatment of moderate-to-severe atopic dermatitis and has shown promising results for the...
8.
Kamphuis E, Loman L, Han H, Romeijn G, Politiek K, Schuttelaar M
Contact Dermatitis
. 2023 Jan;
88(5):351-362.
PMID: 36621910
Background: Real-world data on the effectiveness of upadacitinib on atopic dermatitis (AD), hand eczema (HE) and HE in the context of AD are limited. Objectives: To evaluate the effectiveness and...
9.
Kamphuis E, Boesjes C, Loman L, Bakker D, Poelhekken M, Zuithoff N, et al.
Pediatr Allergy Immunol
. 2022 Dec;
33(12):e13887.
PMID: 36564878
Background: Dupilumab has proven to be an effective and safe treatment for atopic dermatitis (AD) in pediatric patients in clinical trials. However, few daily practice studies are available. The aim...
10.
Boesjes C, Kamphuis E, Zuithoff N, Bakker D, Loman L, Spekhorst L, et al.
Acta Derm Venereol
. 2022 Nov;
102:adv00820.
PMID: 36420885
Clinical trials have shown that baricitinib, an oral selective Janus kinase 1/2 inhibitor, is effective for the treatment of moderate-to-severe atopic dermatitis. However, daily practice data are limited. Therefore, this...